Agree Realty (ADC) Stock

Vancouver, British Columbia--(Newsfile Corp. - November 29, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce its plan to license its proprietary Accum® technology to pharma and biotech companies developing Antibody Drug Conjugates ("ADCs") to amplifying their ADC potency and potentially reducing the dosing. Defence operates on an innovative business model centered around its proprietary Accum® technology, a platform designed to significantly enhance the delivery and efficacy of biologics, including ADCs, radiopharmaceuticals, vaccines, and protein therapeutics.

Realty Income (O) is the 800-pound gorilla in the net lease sector, with a massive $50 billion market cap. It's four times larger than its next closest competitor, and more than six times the size of fast-growing peer Agree Realty (ADC -0.07%).

Macroeconomics trumps politics. REITs are cheap and set to benefit from rate cuts. Here are 3 REITs that win no matter what.

High-yield dividend growth stocks have been on a strong run over the past four months. However, there are several that have not participated in the rally and have even dipped sharply in some cases. We share three examples of high-yielding dividend growers that have strong outlooks but are deeply discounted due to short-term issues.

Nominated IDE034 (BCG034) as a development candidate, a potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC) Option exercised for an exclusive worldwide license for IDE034 from Biocytogen Targeting an IND-filing for IDE034 in 2025 to enable first-in-human clinical evaluation of B7H3/PTK7 topo-I-payload BsADC program IDE034 has the potential to be developed as a monotherapy and in combination with IDEAYA's PARG inhibitor IDE161 B7H3/PTK7 co-expression in lung, colorectal, and head and neck cancer, has been reported at approximately 30%, 46% and 27%, respectively SOUTH SAN FRANCISCO, Calif. and BEIJING , Nov. 11, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the selection of IDE034, a potential first-in-class B7H3/PTK7 topo-I-payload BsADC, as a development candidate and the exercise of its option for an exclusive worldwide license from Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Not everything is perfect in REIT world. On the contrary, this is a sector in which you need to be very selective. Here are 5 types of REITs to avoid at all cost:

Dividend-paying stocks consistently outperform those that don't pay a dividend.

LAUSANNE, Switzerland , Nov. 4, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two investor conferences in November: Guggenheim Securities Healthcare Innovation Conference Date: November 11, 2024 Presentation Time: 11:00 a.m. ET Format: Fireside ChatSpeaker: Ameet Mallik, Chief Executive Officer Jefferies London Healthcare Conference Date: November 19, 2024 Presentation Time: 11:00 a.m.

Dublin, Nov. 04, 2024 (GLOBE NEWSWIRE) -- The "Antibody-Drug Conjugates: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.